for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Westlaw News

Federal Circuit rules Novartis multiple sclerosis drug patent invalid

In a win for three generic drugmakers, a federal appeals court on Wednesday held that Novartis’ patent on the blockbuster multiple sclerosis drug Gilenya was invalid.

A unanimous panel of the U.S. Circuit Court of Appeals for the Federal Circuit affirmed a 2015 ruling by the U.S. Patent Trial and Appeal Board (PTAB), which agreed with generic drugmakers Torrent Pharmaceuticals, Apotex and Mylan Pharmaceuticals that the Gilenya patent was obvious based on a combination of prior innovations.

To read the full story on Westlaw Practitioner Insights, click here: bit.ly/2opFJFV

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up